Drugs / [F-18]DPA714
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06289582 | Aug 2024 → Jun 2028 expected | Parkinson disease | University of Alabama at Birmingham | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [F-18]DPA714 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06289582 ↗ |
| Modality | Diagnostic / imaging agent | “brain PET/MRI imaging after \[F-18\]DPA-714 administration” NCT06289582 ↗ |
| Route | Intravenous | “[F-18]DPA714 administration IV” NCT06289582 ↗ |